EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immunotherapy Administration and Survival for Stage IV Melanoma Patients at Minority‐Serving Hospitals

Mackenzie M Mayhew iD, Zoe Hemmer, Elizabeth J Olecki, Jacob A Sellers, Nidhi Kuchimanchi, Lynn T Dengel, Craig L Slingluff, Russell G Witt

Cancer Medicine · 2026-04 · 15 (4)

DOI: 10.1002/cam4.71834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 15.04.2026. Verfasst von Mackenzie M Mayhew und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Melanoma, Minority Groups, Immunotherapy, Healthcare Disparities. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapy has transformed outcomes in stage IV melanoma, yet disparities in access persist. Minority‐serving hospitals (MSH) disproportionately care for socioeconomically disadvantaged and minority patients, but their impact on immunotherapy use and survival in melanoma is not well defined.

Methods

Adults with stage IV melanoma diagnosed from 2012 to 2020 were identified in the National Cancer Database. MSH were defined as the top decile of institutions by proportion of minority patients with melanoma. Outcomes included immunotherapy receipt and overall survival (OS). Logistic regression assessed predictors of immunotherapy receipt. Cox proportional hazards modeling evaluated OS.

Results

Among 19,469 patients, 1279 (6.6%) were treated at MSH. MSH patients were more often Hispanic (20.6% vs. 1.4%), from lower‐income and less‐educated communities, and had Medicaid or no insurance (all p < 0.001). Immunotherapy was less frequently used at MSH (35.7% vs. 44.7%, p < 0.001). On multivariable analysis, treatment at MSH predicted a lower likelihood of immunotherapy receipt (OR 0.70, 95% CI 0.61–0.81, p < 0.001) and worse OS (HR 1.20, 95% CI 1.07–1.36, p = 0.003).

Conclusions

Stage IV melanoma patients treated at MSH were less likely to receive immunotherapy and had worse survival. These findings highlight institutional disparities beyond patient‐level disadvantage and the need for interventions to strengthen access to life‐prolonging therapies at MSH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaMinority GroupsImmunotherapyHealthcare DisparitiesSkin NeoplasmsHumansFemaleMaleMiddle AgedNeoplasm StagingAgedUnited StatesAdultHospitals

Stichwörter der Autor:innen

immunotherapymetastatic melanomaminority‐serving hospital

Autor:innen und Institutionen

  • Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.
  • Department of Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

ORCID-Profile: Mackenzie M Mayhew

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Mayhew, M. M., Hemmer, Z., Olecki, E. J., Sellers, J. A., Kuchimanchi, N., Dengel, L. T., Slingluff, C. L., & Witt, R. G. (2026). Immunotherapy Administration and Survival for Stage IV Melanoma Patients at Minority‐Serving Hospitals. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71834

Vancouver

Mayhew MM, Hemmer Z, Olecki EJ, Sellers JA, Kuchimanchi N, Dengel LT, et al. Immunotherapy Administration and Survival for Stage IV Melanoma Patients at Minority‐Serving Hospitals. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71834

BibTeX
@article{Mayhew2026,
  author = {Mayhew, Mackenzie M and Hemmer, Zoe and Olecki, Elizabeth J and Sellers, Jacob A and Kuchimanchi, Nidhi and Dengel, Lynn T and Slingluff, Craig L and Witt, Russell G},
  title = {Immunotherapy Administration and Survival for Stage IV Melanoma Patients at Minority‐Serving Hospitals},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cam4.71834}
}
Kostenlos starten →